Antimony

A metallic element that has the atomic symbol Sb, atomic number 51, and atomic weight 121.75. It is used as a metal alloy and as medicinal and poisonous salts. It is toxic and an irritant to the skin and the mucous membranes.

Networked: 940 relevant articles (74 outcomes, 96 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Sundar, Shyam: 21 articles (01/2020 - 12/2002)
2.	Roy, Syamal: 16 articles (01/2022 - 06/2005)
3.	Carvalho, Edgar M: 12 articles (01/2022 - 11/2004)
4.	Sundar, S: 11 articles (01/2009 - 03/2000)
5.	Murray, Henry W: 10 articles (01/2017 - 11/2002)
6.	Thakur, C P: 10 articles (07/2008 - 01/2001)
7.	Frézard, Frédéric: 9 articles (01/2020 - 01/2004)
8.	Ouellette, Marc: 9 articles (01/2018 - 10/2003)
9.	Naskar, Kshudiram: 7 articles (09/2015 - 06/2005)
10.	Chatterjee, Mitali: 7 articles (12/2014 - 02/2007)

Related Diseases

1.	Visceral Leishmaniasis (Kala Azar) 12/01/2005 - "In conclusion, the present study showed that multiple dose treatment with LMA was effective in improving antimony levels in the bone marrow of dogs with visceral leishmaniasis and in reducing the number of positive animals, even though it was not sufficient to achieve complete elimination of parasites." 01/01/2008 - "An aqueous extract of human placenta (HPE) was found to offer protection against established experimental visceral leishmaniasis in BALB/c mice and hamsters, whether the Leishmania donovani strain involved was one that was sensitive or resistant to pentavalent antimony. " 04/08/2013 - "The efficacy of this vaccination regimen in a murine and hamster model of visceral leishmaniasis caused by both antimony resistant (Sb-R) and sensitive (Sb-S) Leishmania (L.) donovani is examined. " 10/15/2008 - "In Bihar, India, home to nearly one-half of the world's burden of visceral leishmaniasis, drug resistance has ended the usefulness of pentavalent antimony, which is the traditional first-line treatment. " 12/01/2002 - "In recent years, there has been a steady erosion in the efficacy of pentavalent antimony to cure visceral leishmaniasis in Bihar, India. "
2.	Cutaneous Leishmaniasis 04/01/1997 - "High-dose long-term regimens of antimony have been shown to be highly effective for the treatment of cutaneous leishmaniasis. " 01/01/1996 - "Systemic monotherapy with IFN-gamma can be an effective treatment for complicated cases of human cutaneous leishmaniasis without the side effects sometimes observed with systemic pentavalent antimony. " 12/01/1997 - "The efficacy of an antimony regimen at the dose of 20 mg/kg/day for a 3-4-week period is well established in the treatment of American cutaneous leishmaniasis. " 06/01/1997 - "In this paper we have studied the efficacy of intralesionally applied antimony in New World cutaneous leishmaniasis. " 04/01/2005 - "Short report: efficacy of pentavalent antimony for treatment of colombian cutaneous leishmaniasis."
3.	Leishmaniasis 06/01/2019 - "In this study, we studied the activity of the antibacterial drugDoxycycline (Russia), and the control was the drug of pentavalent antimony - Glucantim (France), which for a long time was the "gold standard" in the treatment of any form of leishmaniasis. " 04/01/2019 - "The control group is a pentavalent antimony drug - Glucantim (France), which has been the "gold standard" for a long time in the treatment of any form of leishmaniasis. " 06/01/2012 - "For over 60 years, pentavalent antimony (Sb(v)) has been the first-line treatment of leishmaniasis. " 03/01/2012 - "Although various systemic and topical treatments have been proposed for leishmaniasis, pentavalent Antimony compounds remain the first-line treatment for it. " 12/01/2011 - "Drugs based on pentavalent antimony are first-line treatment of the parasite disease leishmaniasis. "
4.	Infections 12/01/2018 - "2HF was effective against promastigotes and the intracellular amastigote form, decreasing the infection index in macrophages infected with wild-type and antimony-resistant promastigotes, but it was not toxic to macrophages. " 06/29/2021 - "The current study provides insight into changes in host splenic B-cell subsets during experimental infection with antimony-sensitive and -resistant L. " 01/01/2022 - "donovani infection irrespective of antimony sensitivity or resistance and mitigate the progression of disease." 01/01/2022 - "Progression of infection in mice by both antimony sensitive and antimony resistant strains of L. " 01/01/2022 - "donovani infection, using both antimony sensitive and antimony resistant L. "
5.	Coma (Comas) 04/01/1990 - "The measuring properties of antimony electrodes were improved by the introduction of highly purified crystallographically oriented monocrystalline antimony (COMA). " 05/01/1997 - "Although, the pH resolution is improved by using highly purified crystallographically oriented monocrystalline antimony (COMA), the oxygen effect on the electrode remains. " 05/01/1997 - "In an in vitro examination of the COMA electrode it was found that the oxygen dependence is similar to that of polycrystalline antimony, i.e. " 01/01/1995 - "Monocrystalline antimony electrodes (crystallographically oriented monocrystalline antimony; COMA) are known to be sensitive to oxygen and to pH. Accordingly, it has been shown that COMA electrodes can be used for the measurement of tissue oxygen tension provided the pH remains constant or is accounted for by the simultaneous use of a glass electrode. " 01/01/2000 - "An electrode of purified, crystallographically orientated monocrystalline antimony (COMA) connected to a reference electrode (silver-silver chloride) was used for the P measurements. "

Related Drugs and Biologics

1.	Sodium
2.	gluconic acid (gluconate)
3.	Amphotericin B (Amphotericin)
4.	Pentamidine (NebuPent)
5.	Interferon-gamma (Interferon, gamma)
6.	liposomal amphotericin B
7.	Pentoxifylline (Trental)
8.	Antimony Sodium Gluconate (Sodium, Stibogluconate)
9.	Meglumine Antimoniate
10.	Colloids (Colloid)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Electrodes (Electrode)
4.	Cryotherapy (Therapy, Cold)
5.	Intravenous Injections